Please upgrade your browser.
Priority is anti-tumor effects. Everything else, however severe, is considered the price worth paying.
Dr Michele Teng, who led the study, said if they results were replicated in humans it could lead to widespread changes in oncology practices
Pfizer and Merck KGaA have moved closer to bringing the fourth checkpoint inhibitor to the US market after the FDA granted a priority review for the drug in a rare form of skin cancer.
Examination of the TCGA RNA-seq dataset also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples.
...these approaches allow oncologists to examine tissue samples and learn more about how these drugs affect the primary tumor - See more at: http://www.onclive.com/onclive-tv/dr-margulis-on-different-approaches-to-adjuvant-therapy-in-rcc#sthash.RO7Md4Zh.dpuf
The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer...
Italian researchers found that people whose diets are rich in onions, garlic, and other alliums have a much lower risk of several types of cancer than those who avoid the pungent herbs.
Together, this research offers some of the strongest evidence to date of a link between diet and cancer, the study authors said
An update on two unusual cases from this Phase 2 study with intermediate risk mRCC, who obtained long term control of metastatic disease that is remarkably still ongoing nearly seven years after initiation of AGS-003 therapy.
|Powered by NeonCRM|